Hemispherx Biopharma's CEO to Attend BioFlorida Inc.’s 2019 Celebration of Biotechnology
May 08 2019 - 8:30AM
(NYSE American: HEB) — Hemispherx Biopharma Inc.’s CEO Thomas K.
Equels will be attending the 2019 Celebration of Biotechnology
where he’ll meet with investors and industry representatives to
discuss the company’s recent successes and plans for the future.
Hemispherx is an immuno-pharma company focused on the research and
development of therapeutics to treat multiple types of cancers, as
well as immune-deficiency disorders.
The BioFlorida Inc. sponsored event is being held May 9 at
Foundation Park, 14193 NW 119th Terrace, Alachua, Fla., 32615.
Approximately 100 life sciences exhibitors and more than 500
industry professionals are expected to attend.
Equels' meetings will focus on the company’s ongoing clinical
trials and programs using its flagship investigational drug
Ampligen in multiple cancer types. The company recently announced
significant progress in its Ampligen pancreatic cancer program and
multiple Ampligen-plus-checkpoint-blockade immuno-oncology
programs, including additional planned trials at major research
institutes, subject to obtaining funding. Hemispherx will be
studying the effect of Ampligen on nine different solid tumor
types: pancreatic, ovarian, colorectal, prostate, lung, bladder,
breast, melanoma and renal cell carcinoma.
See a full immuno-oncology update here:
https://hemispherx.irpass.com/Hemispherx-Biopharma-Announces-Significant-Progress-in-its-Ampligen-Pancreatic-Cancer-Program-and-Mu
Learn more about the event:
https://www.bioflorida.com/page/Celebration19
About BioFlorida
BioFlorida represents 6,200 establishments and research
organizations in the biopharmaceuticals, medical technology,
healthIT and bioagriculture sectors that collectively employ 87,000
Floridians. Members of the BioFlorida network include emerging and
established life science companies, universities, research
institutions, hospitals, medical centers, incubators, economic
development agencies, investors and service providers.
About Hemispherx Biopharma
Hemispherx Biopharma, Inc. is an immuno-pharma company focused
on the research and development of therapeutics to treat multiple
types of cancers, as well as immune-deficiency disorders.
Hemispherx's flagship products include the Argentina-approved drug
rintatolimod (trade names Ampligen® or Rintamod®) and the
FDA-approved drug Alferon N Injection®. Based on results of
published, peer-reviewed pre-clinical studies and clinical trials,
Hemispherx believes that Ampligen® may have broad-spectrum
anti-viral and anti-cancer properties. Clinical trials of Ampligen®
already conducted include studies of the potential treatment of
cancer patients with renal cell carcinoma and malignant melanoma.
These and other potential uses will require additional clinical
trials to generate the safety and effectiveness data necessary to
support regulatory approval. Rintatolimod is a double-stranded RNA
being developed for globally important debilitating diseases and
disorders of the immune system.
Cautionary Statement
Some of the statements included in this press release may be
forward-looking statements that involve a number of risks and
uncertainties. Among other things, for those statements, we claim
the protection of the safe harbor for forward-looking statements
contained in the Private Securities Litigation Reform Act of 1995.
Any forward-looking statements set forth in this press release
speak only as of the date of this press release. We do
not undertake to update any of these forward-looking statements to
reflect events or circumstances that occur after the date hereof.
This press release and prior releases are available at
www.hemispherx.net. The information found on our website is not
incorporated by reference into this press release and is included
for reference purposes only.
Contacts:
Hemispherx Biopharma, Inc.Phone: 800-778-4042Email:
IR@hemispherx.net
Or
LHA Investor RelationsMiriam Weber MillerSenior Vice
PresidentPhone: +1-212-838-3777Email: mmiller@lhai.com
Hemispherx Biopharma (AMEX:HEB)
Historical Stock Chart
From Apr 2024 to May 2024
Hemispherx Biopharma (AMEX:HEB)
Historical Stock Chart
From May 2023 to May 2024